Evaluation of Single Doses of GSK962040 in Critically Ill Patients With Enteral Feed Intolerance

Phase 2

Completed

Conditions: Gastroparesis

Interventions: Drug: GSK962040 (50 mg)
Drug: Placebo
Drug: GSK962040 (75 mg)

Registration Number: NCT01039805

Lead Sponsor: GlaxoSmithKline

Brief Summary: The aims of MOT112571 are to assess the pharmacodynamic effects, safety, tolerability, pharmacokinetics, and potential therapeutic benefit of single doses of GSK962040 in critically ill patients with delayed gastric emptying and who are intolerant to enteral feeding.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 34

Inclusion Criteria

Male or female between 18-85 years of age, at the time consent is obtained.
Mechanically ventilated on the Intensive Care Unit who has become intolerant of nasogastric enteral feeding.
intolerance of nasogastric tube feeding is defined as a gastric aspirate volume (GRV) >250 mL at least 6 hours after commencing feeding at >40 mL/hr.
Expected to remain mechanically ventilated for at least 48 hours after enrollment and expected to survive for at least 24 hours post dose of study medication.
Subject has a nasogastric tube for enteral feeding.
Body weight > or = 50 kg
Written informed consent may be obtained from a legally acceptable representative, which includes compliance with the requirements and restrictions listed in the consent form. In most cases, consent will be sought from next of kin as the subject will not be competent to give their own consent.
Average QTcB or QTcF < 450 msec; or QTc < 480 msec in subjects with Bundle Branch Block.
AST and ALT < 3xULN; alkaline phosphatase and bilirubin < or = 2xULN.
Subjects who have rapidly rising aminotransferases or for whem there is not a plausible explanation for the observed elevation will not be enrolled
LFTs will be checked for eligibility on screening and again prior to dosing with GSK962040.

Exclusion Criteria

Subjects that have received a gastric prokinetic agent in the previous 24 h (e.g., erythromycin, azithromycin, metoclopramide). These agents are prohibited for the duration of the study.
Subjects whose clinical condition is deteriorating rapidly or any subject for whom the investigator does not consider there is a reasonable expectation that they will be able to complete the study.
Subjects who are known to be infected with Hepatitis B, Hepatitis C, or HIV viruses.
Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
Use of prohibited medications listed in Section 9.2 within the restricted timeframe relative to dosing of study medication.
Subjects with renal failure requiring replacement therapy (dialysis or filtration).
Subjects for whom the reason for admission to ICU was an overdose (deliberate or accidental; medicinal product or not).
Subjects with altered upper gastrointestinal tract anatomy and subjects who have undergone upper gastrointestinal tract surgery on this admission to ICU.
Subjects with bowel obstruction or perforation.
Subject has a gastric pacemaker
Subject is receiving parenteral feeding
History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
Pregnant females as determined by positive serum or urine hCG test at screening or prior to dosing.
Lactating females.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Cohort 1	GSK962040 (50 mg)	Subjects randomized to either GSK962040 (50 mg) or placebo
Cohort 2	Placebo	Subjects randomized to either GSK962040 (75 mg) or placebo
Cohort 1	Placebo	Subjects randomized to either GSK962040 (50 mg) or placebo
Cohort 2	GSK962040 (75 mg)	Subjects randomized to either GSK962040 (75 mg) or placebo

Primary Outcome Measures

Name	Time	Method
Gastric emptying	3 days
Safety and tolerability of GSK962040	5 days
Pharmacokinetic parameters of GSK962040: Cmax, Tmax, AUC(0-inf), AUC(0-t), CL/F, V/F, and half-life	3 days

Secondary Outcome Measures

Name	Time	Method
Pre and post GSK962040 dose Gastric Residual Volume (GRV)	Duration of dosing
Pharmacokinetic parameters of paracetamol	duration of dosing
Pharmacokinetic parameters of 3OMG	duration of dosing
Plasma concentrations of motilin	duration of dosing